Herantis Pharma announces FDA clearance of IND for Phase 2 study of Cis-UCA Eye Drops Herantis Pharma plc. Company release 8 September 2014 at 8:30 a.m. The United States Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) of Herantis Pharma Plc. for a Phase 2 clinical study of Cis-UCA Eye Drops for the treatment of Dry Eye Syndrome. Patient enrolment in the clinical study is planned to start by the end of 2014. "Dry Eye Syndrome has surprisingly limited treatment options considering it is such a common eye disease", says Burkhard Blank, MD, Chief Medical Officer of Herantis. "There is currently only one FDA-approved prescription drug in the market in the USA and none in the EU. We believe that Cis-UCA Eye Drops have the potential to provide an effective and safe treatment for many patients affected by Dry Eye Syndrome." The Phase 2 clinical study will be conducted at three investigational sites in the USA by Ora, Inc., the world's leading independent, full-service ophthalmic clinical research and product development firm, who has worked with Herantis' cis-UCA for the past three years. The study is designed to enrol a total of 150 patients randomized in three treatment groups receiving either placebo or one of two different doses of Cis-UCA Eye Drops, using Ora's Controlled Adverse Environment (CAE) dry eye system. The objective of the study is to compare the safety and efficacy of Cis-UCA Eye Drops to placebo, for the treatment of the signs and symptoms of Dry Eye Syndrome. "An estimated 45 million patients in the USA and in Europe suffer from Dry Eye Syndrome", adds Pekka Simula, CEO of Herantis Pharma. "We are truly excited to reach this important milestone in our development of new, innovative drugs and look forward to helping patients in need of better treatments." Further information: Herantis Pharma plc., Pekka Simula, CEO, telephone: +358 40 7300 445 Company web site: www.herantis.com Certified Advisor: UB Capital Oy, telephone +358 9 2538 0225 About Dry Eye Syndrome Dry Eye Syndrome (Keratoconjunctivitis sicca) is the most common cause of irritation in the eye. Typical subjective symptoms include dryness, burning sensation, pain, redness, and feeling of dirt in the eye. A severe or prolonged Dry Eye Syndrome may lead to complications causing damage to the surface of the eye and impaired vision. Dry Eye Syndrome is expected to become more prevalent with the aging population and with increasing use of computers and mobile devices. About Cis-UCA Eye Drops Cis-UCA Eye Drops is an ophthalmic solution indicated for the treatment of the signs and symptoms of Dry Eye Syndrome. Cis-urocanic acid (Cis-UCA), the active product ingredient of Cis-UCA Eye Drops, is an endogenous small molecule component of human and animal skin. It is constantly present in the human body and has been identified as a locally acting anti-inflammatory agent, which also reduces free radicals. Cis-UCA Eye Drops has previously been investigated in an experimental model of dry eye in the mouse, conducted by Ora to simulate the CAE clinical model to be used in the Phase 2 clinical study. The results indicate that 1% Cis-UCA Eye Drops is efficacious in reducing corneal fluorescein staining in the model and performs better than the clinical comparator, Restasis®. Based on an earlier Phase 1 clinical study in 37 healthy volunteers, cis-UCA Eye Drops is expected to be safe and well tolerated in human subjects enrolled in the proposed Phase 2 clinical study. About Herantis Pharma plc. Herantis Pharma plc. is a pharmaceutical company specialised in new drug research and development. The company focuses on diseases with an unmet clinical need. These diseases include for example dry eye syndrome, Parkinson's disease, and secondary lymphedema. We believe our drugs are the first or best in their class and have the potential to change treatment strategies of diseases. The shares of Herantis Pharma plc. are listed on the First North Finland marketplace run by NASDAQ OMX Helsinki stock exchange. [HUG#1854085]
Herantis Pharma announces FDA clearance of IND for Phase 2
Top 10 Most Recent News Articles
AdMaven's Mave AI: Revolutionizing Campaign Management
Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...
Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers
Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...
Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?
A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...
Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo
ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...
Continue Reading
DarioHealth's New Research Tackles Healthcare Cost Estimation
Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...
Continue Reading
Alliance for Women in Media Champions Change in 2026
A Celebration of Trailblazing Women in Media If there's one thing I've learned about strong leadership, it's that you can't fake authenticity. Today, we're tipping our hats to some genuine trailblazers. The Alliance for Women in Media (AWM) held its annual Gracies Leadership Awards, celebrating the achievements and vision of seven remarkable women. Honoring the...
Continue Reading
Lennar Faces Legal Heat Over Alleged Misleading Statements
Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...
Continue Reading
Caladan Partners with Anchorage for Stronger Trading
Caladan and Anchorage Unite for Asset Growth Man, partnerships might just be the secret sauce we never know we need until it’s on our plate. It's a fresh day in digital trading, and Caladan just shook things up by teaming up with Anchorage Digital, bolstering their trading and settlement capabilities to satisfy the big players. If there's one thing that's hot as a...
Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments
Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....
Continue Reading
Dr. Obeng Joins WellcomeMD with Special Offer for Patients
New Beginnings in Concierge Medicine In late October, WellcomeMD opened its doors to Dr. Paa-Kofi Obeng—an arrival greeted with considerable anticipation in Richmond's medical scene. This isn't just any run-of-the-mill staff addition; Dr. Obeng brings with him over a decade of experience from places like the Veterans Administration Medical Center. He's armed with a...
Continue ReadingTop 5 Most Recently Viewed Articles
Celebrating Consumer Trust: The Most Trusted Brands of 2026
Consumer Trust at the Core of Shopping Decisions In an ever-competitive marketplace, consumers face an overwhelming array of choices, making decisions increasingly challenging. Fortunately, trust acts as a guiding beacon for shoppers, allowing them to confidently narrow down their options when making purchases. According to the BrandSpark American Trust Study, a...
Continue Reading
Saudi AI Hackathon 2025: Empowering Student Innovators
Saudi AI & Edge Computing Hackathon 2025 Fosters Innovation In a remarkable showcase of talent and creativity, the Saudi AI & Edge Computing Hackathon 2025 took center stage, emphasizing the synergy between academia and the tech industry. Hosted by Prince Sultan University and backed by MemryX, this hackathon highlighted the exceptional capabilities of students from...
Continue Reading
Meta Implements AI Hiring Freeze Amid Talent Competition
Meta Platforms Inc. Takes a Step Back in AI Hiring Meta Platforms Inc. (NASDAQ: META) has recently instituted a hiring freeze in its artificial intelligence division. This decision follows months of aggressive recruitment, during which the company significantly boosted its talent pool with substantial compensation offers. The freeze is aimed at regulating the hiring...
Continue Reading
Lady Gaga's Heartfelt Cover of 'Won't You Be My Neighbor?' in Super Bowl Teaser
Lady Gaga Celebrates Community with New Cover In a touching tribute to the spirit of neighborliness, Lady Gaga has graced the world with her cover of "Won't You Be My Neighbor?". This initiative is part of a larger campaign that dives deep into themes of home, community, and belonging. Behind the Scenes of the Teaser Fans can catch exclusive behind-the-scenes footage...
Continue Reading
Palo Alto Networks Plummets: Guidance Cut or Market Misread?
Palo Alto Networks took a nosedive, with shares down over 7% premarket, sitting at $151.69—a shocker for traders who were banking on bullish momentum. The cybersecurity giant's fiscal second-quarter report dropped Tuesday, revealing a mixed bag that left investors scrambling to recalibrate expectations. While the top line reported $2.59 billion in revenue—just edging...
Continue Reading